MAC Clinical Research is proud to have partnered with Gilgamesh Pharma in the successful completion of a Phase 2a clinical trial evaluating Blixeprodil (GM-1020), a novel oral NMDA receptor antagonist, for the treatment of Major Depressive Disorder (MDD).
The study demonstrated rapid, robust and durable antidepressant effects following a short course of treatment, with topline data showing a statistically significant and clinically meaningful benefit over placebo.
Key findings include:
- A 6.3-point greater reduction in MADRS (Montgomery-Åsberg Depression Rating Scale) scores versus placebo, observed just 24 hours after a single dose of blixeprodil
- Following twice-weekly dosing over a 2-week period, the therapeutic benefit was durable through 28 days of follow-up without further treatment
- Blixeprodil was safe and well-tolerated, with no serious adverse events reported in the trial
This innovative compound is designed to modulate NMDA receptor activity without dissociative side effects, offering a novel and potentially transformative approach to depression treatment.
Talking about the study results and MAC’s role in the project, Dr John Connell, Chief Scientific Officer at MAC, said:
“It’s been a pleasure to work with the Gilgamesh team on this programme. Blixeprodil is a fascinating compound, and these results are incredibly encouraging. Not just because of the rapid onset and durability of effect but also because the safety and tolerability profile looks so promising. At MAC, we’re always excited to be involved in cutting-edge neuroscience research, especially when it has the potential to address such a significant unmet need. We’re proud to have helped deliver this important study and the data emerging from it.”
To read the full press release from Gligamesh Pharma click here.
